Evidence map›Paper›PMID 29023446›Full record

ReviewPLoS neglected tropical diseases2017

Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.

Siddhivinayak Hirve, Axel Kroeger, Greg Matlashewski, Dinesh Mondal, Megha Raj Banjara, Pradeep Das, Ahmed Be-Nazir, Byron Arana, Piero Olliaro

Open access · goldAbstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Detection ofPathogens (Basel, Switzerland) · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Siddhivinayak HirveGlobal Influenza Programme, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-9651-7789
Axel KroegerCentre for Medicine and Society and Centre for Anthropology, Freiburg University, Freiburg, Germany.
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, Montreal, Canada.
Dinesh MondalNutrition and Clinical Services division, International Center for Diarrheal Disease Research Bangladesh, Dhaka, Bangladesh.
Megha Raj BanjaraCentral Department of Microbiology, Tribhuvan University, Kathmandu, Nepal.
Pradeep DasRajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Patna, India.
Ahmed Be-NazirDepartment of Microbiology and Parasitology, National Institute of Preventive and Social Medicine, Dhaka, Bangladesh.
Byron AranaCutaneous Leishmaniasis unit, Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
Piero OlliaroSpecial Programme for Research and Training in Tropical Diseases (TDR), hosted by the World Health Organization, Geneva, Switzerland.
World Health Organization · CHDrugs for Neglected Diseases Initiative · CHInternational Centre for Diarrhoeal Disease Research · BDMcGill University · CANational Institute of Cardiovascular Diseases · BDRajendra Memorial Research Institute of Medical Sciences · INTribhuvan University · NPUniversity of Freiburg · DE

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe decade following the Regional Strategic Framework for Visceral Leishmaniasis (VL) elimination in 2005 has shown compelling progress in the reduction of VL burden in the Indian subcontinent. The Special Programme for Research and Training in Tropical Diseases (TDR), hosted by the World Health Organization (WHO) and other stakeholders, has coordinated and financed research for the development of new innovative tools and strategies to support the regional VL elimination initiative. This paper describes the process of the TDR's engagement and contribution to this initiative. METHODOLOGY/PRINCIPAL

findingsMultiple databases were searched to identify 152 scientific papers and reports with WHO funding or authorship affiliation around the following 3 framework strategies: detection of new cases, morbidity reduction, and prevention of infection. TDR has played a critical role in the evaluation and subsequent use of the 39-aminoacid-recombinant kinesin antigen (rK39) rapid diagnostic test (RDT) as a confirmatory test for VL in the national program. TDR has supported the clinical research and development of miltefosine and single-dose liposomal amphotericin B as a first-line treatment against VL. TDR has engaged with in-country researchers, national programme managers, and partners to generate evidence-based interventions for early detection and treatment of VL patients. TDR evaluated the quality, community acceptance, and cost effectiveness of indoor residual spraying, insecticide-treated bed nets, insecticide-impregnated durable wall linings, insecticidal paint, and environmental management as tools for integrated vector management in reducing sandfly density. CONCLUSIONS/SIGNIFICANCE: TDR's engagement with country policy makers, scientists, and clinicians in the development of effective diagnosis, treatment, case detection, and vector control represents an important example of TDR's stewardship toward the elimination of VL in the Indian subcontinent.

Indexed as

Disease EradicationPublic Health PracticeTranslational Research, BiomedicalAnimalsHumansIndiaInsect ControlInsecticidesInsecticide-Treated BednetsInsect VectorsLeishmaniasis, VisceralPhlebotomusWorld Health OrganizationInsecticides

Identifiers

PMID29023446
PMCPMC5638223
OpenAlexW2761957416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.